| 6ZRU |
X-RAY DIFFRACTION |
2.1 |
Crystal structure of SARS CoV2 main protease in complex with inhibitor Boceprevir |
Crystal structure of SARS CoV2 main protease in complex with inhibitor Boceprevir |
rep, 1a-1b |
Main Protease |
Boceprevir |
~ |
To be published |
3D view |
| 6ZRT |
X-RAY DIFFRACTION |
2.1 |
Crystal structure of SARS CoV2 main protease in complex with inhibitor Telaprevir |
Crystal structure of SARS CoV2 main protease in complex with inhibitor Telaprevir |
rep, 1a-1b |
Main Protease |
Telaprevir |
~ |
To be published |
3D view |
| 6ZXN |
ELECTRON MICROSCOPY |
2.93 |
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. |
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing nanobodies (Ty1) |
S, 2 |
Spike glycoprotein |
Nanobody Ty1 |
~ |
32887876 |
3D view |
| 7A29 |
ELECTRON MICROSCOPY |
2.94 |
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. |
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) 2-up conformation |
S, 2 |
Spike glycoprotein |
Neutralising sybody (Sb23) |
~ |
33149112 |
3D view |
| 7A25 |
ELECTRON MICROSCOPY |
3.06 |
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. |
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) |
S, 2 |
Spike glycoprotein |
Sybody 23 |
~ |
33149112 |
3D view |
| 7A1U |
X-RAY DIFFRACTION |
1.67 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Fusidic Acid. |
|
Main Protease |
Fusidic Acid |
~ |
Biorxiv |
3D view |
| 7A5S |
ELECTRON MICROSCOPY |
3.9 |
Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. |
Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement) |
S, 2 |
Spike glycoprotein |
CR3022 Fab Heavy Chain
CR3022 Fab Light Chain |
~ |
33087721 |
3D view |
| 7A5R |
ELECTRON MICROSCOPY |
3.7 |
Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. |
Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement) |
S, 2 |
Spike glycoprotein |
CR3022 Fab Heavy Chain
CR3022 Fab Light Chain |
~ |
33087721 |
3D view |
| 7A98 |
ELECTRON MICROSCOPY |
5.4 |
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. |
SARS-CoV-2 Spike Glycoprotein with 3 ACE2 Bound |
S, 2 |
Spike glycoprotein |
Angiotensin-converting enzyme 2 |
ACE2
UNQ868/PRO1885 |
32942285 |
3D view |
| 7A97 |
ELECTRON MICROSCOPY |
4.4 |
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. |
SARS-CoV-2 Spike Glycoprotein with 2 ACE2 Bound |
S, 2 |
Spike glycoprotein |
Angiotensin-converting enzyme 2 |
ACE2
UNQ868/PRO1885 |
32942285 |
3D view |
| 7A92 |
ELECTRON MICROSCOPY |
4.2 |
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. |
Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Unmasked Refinement) |
S, 2 |
Spike glycoprotein |
Angiotensin-converting enzyme 2 |
ACE2
UNQ868/PRO1885 |
32942285 |
3D view |
| 7A91 |
ELECTRON MICROSCOPY |
3.6 |
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. |
Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
S, 2 |
Spike glycoprotein |
Angiotensin-converting enzyme 2 |
ACE2
UNQ868/PRO1885 |
32942285 |
3D view |
| 7A94 |
ELECTRON MICROSCOPY |
3.9 |
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. |
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound |
S, 2 |
Spike glycoprotein |
Angiotensin-converting enzyme 2 |
ACE2
UNQ868/PRO1885 |
32942285 |
3D view |
| 7A96 |
ELECTRON MICROSCOPY |
4.8 |
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. |
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Anticlockwise Direction |
S, 2 |
Spike glycoprotein |
Angiotensin-converting enzyme 2 |
ACE2
UNQ868/PRO1885 |
32942285 |
3D view |
| 7A95 |
ELECTRON MICROSCOPY |
4.3 |
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. |
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Clockwise Direction |
S, 2 |
Spike glycoprotein |
Angiotensin-converting enzyme 2 |
ACE2
UNQ868/PRO1885 |
32942285 |
3D view |
| 6Z43 |
ELECTRON MICROSCOPY |
3.3 |
Structural basis for a potent neutralising single-domain antibody that blocks SARS-CoV-2 binding to its receptor ACE2 |
Cryo-EM Structure of SARS-CoV-2 Spike : H11-D4 Nanobody Complex |
S, 2 |
Spike glycoprotein |
Nanobody |
~ |
To be published |
3D view |
| 7AAP |
ELECTRON MICROSCOPY |
2.5 |
Nsp7-Nsp8-Nsp12 SARS-CoV2 RNA-dependent RNA polymerase in complex with template:primer dsRNA and favipiravir-RTP |
Nsp7-Nsp8-Nsp12 SARS-CoV2 RNA-dependent RNA polymerase in complex with template:primer dsRNA and favipiravir-RTP |
rep, 1a-1b |
NSP12, NSP8,NSP7 |
RNA (5'-R(P*UP*UP*AP*AP*GP*UP*UP*AP*U)-3')
RNA (5'-R(P*UP*UP*CP*AP*UP*AP*AP*CP*UP*UP*AP*A)-3')
|
~ |
To be published |
3D view |
| 6YT8 |
X-RAY DIFFRACTION |
2.05 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to pyrithione zinc |
rep, 1a-1b |
Replicase polyprotein 1ab |
pyrithione zinc |
~ |
A0BiorxivA0 |
3D view |
| 7ABU |
X-RAY DIFFRACTION |
1.6 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to RS102895 |
rep, 1a-1b |
Main Protease |
RS102895 |
~ |
A0BiorxivA0 |
3D view |
| 6Z72 |
X-RAY DIFFRACTION |
2.3 |
Viral macrodomains: a structural and evolutionary assessment of the pharmacological potential. |
SARS-CoV-2 Macrodomain in complex with ADP-HPM |
rep, 1a-1b |
Replicase polyprotein 1ab |
ADP-HPM |
~ |
33202171 |
3D view |
| 6Z6I |
X-RAY DIFFRACTION |
2 |
Viral macrodomains: a structural and evolutionary assessment of the pharmacological potential. |
SARS-CoV-2 Macrodomain in complex with ADP-HPD |
rep, 1a-1b |
Replicase polyprotein 1ab |
ADP-HPD |
~ |
33202171 |
3D view |
| 6Z5T |
X-RAY DIFFRACTION |
1.571 |
Viral macrodomains: a structural and evolutionary assessment of the pharmacological potential. |
SARS-CoV-2 Macrodomain in complex with ADP-ribose |
rep, 1a-1b |
Replicase polyprotein 1ab |
ADP-ribose |
~ |
33202171 |
3D view |
| 7ACT |
SOLUTION NMR |
|
The SARS-CoV-2 nucleocapsid phosphoprotein N-terminal domain in complex with 10mer ssRNA |
The SARS-CoV-2 nucleocapsid phosphoprotein N-terminal domain in complex with 10mer ssRNA |
N |
Nucleoprotein |
10mer ssRNA |
~ |
33264373 |
3D view |
| 7ACS |
SOLUTION NMR |
|
The SARS-CoV-2 nucleocapsid phosphoprotein N-terminal domain in complex with 7mer ssRNA |
The SARS-CoV-2 nucleocapsid phosphoprotein N-terminal domain in complex with 7mer dsRNA |
N |
Nucleoprotein |
RNA (5'-R(P*CP*AP*CP*UP*GP*AP*C)-3')
RNA (5'-R(P*GP*UP*CP*AP*GP*UP*G)-3') |
~ |
A033264373A0 |
3D view |
| 6YVF |
X-RAY DIFFRACTION |
1.6 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to AZD6482. |
rep, 1a-1b |
Replicase polyprotein 1ab |
AZD6482 |
~ |
|
3D view |
| 6YVA |
X-RAY DIFFRACTION |
3.18 |
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. |
PLpro-C111S with mISG15 |
rep, 1a-1b |
Replicase polyprotein 1a |
Ubiquitin-like protein ISG15 |
Isg15, G1p2, Ucrp,
|
32726803 |
3D view |
| 6YWM |
X-RAY DIFFRACTION |
2.16 |
Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with MES |
Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with MES |
rep, 1a-1b |
NSP3 macrodomain |
MES [
2-(N-MORPHOLINO)-ETHANESULFONIC ACID ] |
~ |
|
3D view |
| 6YWL |
X-RAY DIFFRACTION |
2.5 |
Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with ADP-ribose |
Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with ADP-ribose |
rep, 1a-1b |
NSP3 macrodomain |
ADP-ribose |
~ |
|
3D view |
| 7ADW |
X-RAY DIFFRACTION |
1.63 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to 2,4'-Dimethylpropiophenone. |
rep, 1a-1b |
Main Protease |
2,4'-Dimethylpropiophenone |
~ |
|
3D view |
| 6YWK |
X-RAY DIFFRACTION |
2.2 |
Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with HEPES |
Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with HEPES |
rep, 1a-1b |
NSP3 macrodomain |
HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) |
~ |
|
3D view |
| 6YZ1 |
X-RAY DIFFRACTION |
2.4 |
Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin. |
The crystal structure of SARS-CoV-2 nsp10-nsp16 methyltransferase complex with Sinefungin |
rep, 1a-1b |
nsp16, nsp10 |
Sinefungin |
~ |
32709887 |
3D view |
| 6YZ6 |
X-RAY DIFFRACTION |
1.7 |
Structure of the hemiacetal complex between the SARS-CoV-2 Main Protease and Leupeptin |
Structure of the hemiacetal complex between the SARS-CoV-2 Main Protease and Leupeptin |
rep, 1a-1b |
Main Protease |
Leupeptin |
~ |
To be published |
3D view |
| 6YYT |
ELECTRON MICROSCOPY |
2.9 |
Structure of replicating SARS-CoV-2 polymerase. |
Structure of replicating SARS-CoV-2 polymerase |
|
nsp12,nsp8, nsp7, |
RNA product |
~ |
32438371 |
3D view |
| 6YZ5 |
X-RAY DIFFRACTION |
1.8 |
H11-D4 complex with SARS-CoV-2 RBD |
H11-D4 complex with SARS-CoV-2 RBD |
S, 2 |
Spike glycoprotein |
Nanobody H11-D4 |
~ |
To be published |
3D view |
| 6YZ7 |
X-RAY DIFFRACTION |
3.3 |
Structural characterisation of a nanobody derived from a naive library that neutralises SARS-CoV-2 |
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex |
S, 2 |
Spike glycoprotein |
Antibody Cr3022, Antibody light chain, Nanobody |
~ |
To be published |
3D view |
| 7AGA |
X-RAY DIFFRACTION |
1.68 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to AT7519 |
rep, 1a-1b |
Main Protease |
AT7519 |
~ |
|
3D view |
| 7AHA |
X-RAY DIFFRACTION |
1.68 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Maleate. |
rep, 1a-1b |
Main Protease |
Maleate |
~ |
|
3D view |
| 7AK4 |
X-RAY DIFFRACTION |
1.63 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Tretazicar. |
rep, 1a-1b |
Main Protease |
Tretazicar |
~ |
|
3D view |
| 7AKU |
X-RAY DIFFRACTION |
2.5 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Calpeptin. |
rep, 1a-1b |
Replicase polyprotein 1ab |
Calpeptin |
~ |
|
3D view |
| 7AMJ |
X-RAY DIFFRACTION |
1.59 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to PD 168568. |
rep, 1a-1b |
Main Protease |
PD 168568 |
~ |
|
3D view |
| 6ZBP |
X-RAY DIFFRACTION |
1.85 |
H11-D4 complex with SARS-CoV-2 RBD |
H11-H4 complex with SARS-CoV-2 |
S, 2 |
Spike glycoprotein |
H11-H4 |
~ |
|
3D view |
| 7ANS |
X-RAY DIFFRACTION |
1.7 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Adrafinil. |
rep, 1a-1b |
Main Protease |
Adrafinil |
~ |
|
3D view |
| 6ZCZ |
X-RAY DIFFRACTION |
2.65 |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody. |
S, 2 |
Spike glycoprotein |
Nanobody, EY6A heavy chain, EY6A light chain |
~ |
32737466 |
3D view |
| 7AP6 |
X-RAY DIFFRACTION |
1.78 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to MUT056399. |
rep, 1a-1b |
Main Protease |
MUT056399 |
~ |
|
3D view |
| 7AOL |
X-RAY DIFFRACTION |
1.47 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Climbazole |
ORF1ab |
ORF1ab polyprotein |
Climbazole |
~ |
|
3D view |
| 6ZDH |
ELECTRON MICROSCOPY |
3.7 |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab |
S, 2 |
Spike glycoprotein |
EY6A heavy chain, EY6A light chain |
~ |
32737466 |
3D view |
| 7APH |
X-RAY DIFFRACTION |
1.65 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Tofogliflozin. |
rep, 1a-1b |
Main Protease |
Tofogliflozin |
~ |
|
3D view |
| 6ZDG |
ELECTRON MICROSCOPY |
4.7 |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab |
S, 2 |
Spike glycoprotein |
EY6A heavy chain, EY6A light chain |
~ |
32737466 |
3D view |
| 7ARF |
X-RAY DIFFRACTION |
2 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to thioglucose. |
rep, 1a-1b |
Main Protease |
thioglucose |
~ |
|
3D view |
| 6ZER |
X-RAY DIFFRACTION |
3.8 |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab |
S, 2 |
RBD |
EY6A Fab |
~ |
32737466 |
3D view |
| 7AQJ |
X-RAY DIFFRACTION |
2.59 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Triglycidyl isocyanurate. |
rep, 1a-1b |
Main Protease |
Triglycidyl isocyanurate |
~ |
|
3D view |
| 7AQI |
X-RAY DIFFRACTION |
1.7 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to Ifenprodil |
rep, 1a-1b |
Main Protease |
Ifenprodil |
~ |
|
3D view |
| 6ZFO |
ELECTRON MICROSCOPY |
4.4 |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab |
S, 2 |
Spike glycoprotein |
EY6A heavy chain, EY6A light chain |
~ |
32737466 |
3D view |
| 7B3O |
X-RAY DIFFRACTION |
2 |
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations |
Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab |
S |
Surface glycoprotein |
STE90-C11 Fab |
~ |
|
3D view |
| 6ZH9 |
X-RAY DIFFRACTION |
3.31 |
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. |
Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2) |
S,2 |
Spike glycoprotein |
CR3022 heavy chain, CR3022 Light chain, Nanobody H11-H4 |
~ |
32661423 |
3D view |
| 6ZHD |
ELECTRON MICROSCOPY |
3.7, 3.7 |
H11-H4 bound to Spike |
H11-H4 bound to Spike |
S,2, wac |
Spike glycoprotein,Fibritin |
Nanobody H11-H4 |
~ |
|
3D view |
| 6ZME |
ELECTRON MICROSCOPY |
3 |
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. |
SARS-CoV-2 Nsp1 bound to the human CCDC124-80S-eERF1 ribosome complex |
rep, 1a-1b |
nsp1 |
CCDC124-80S-eERF1 ribosome complex |
~ |
32680882 |
3D view |
| 6ZLW |
ELECTRON MICROSCOPY |
2.6 |
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. |
SARS-CoV-2 Nsp1 bound to the human 40S ribosomal subunit |
rep, 1a-1b |
nsp1 |
40S ribosomal subunit complex |
~ |
32680882 |
3D view |
| 6ZM7 |
ELECTRON MICROSCOPY |
2.7 |
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. |
SARS-CoV-2 Nsp1 bound to the human CCDC124-80S-EBP1 ribosome complex |
rep, 1a-1b |
nsp1 |
human CCDC124-80S-EBP1 ribosome complex |
~ |
32680882 |
3D view |
| 6ZMT |
ELECTRON MICROSCOPY |
3 |
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. |
SARS-CoV-2 Nsp1 bound to a pre-40S-like ribosome complex |
rep, 1a-1b |
nsp1 |
pre-40S-like ribosome complex |
~ |
32680882 |
3D view |
| 6ZN5 |
ELECTRON MICROSCOPY |
3.2 |
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. |
SARS-CoV-2 Nsp1 bound to a pre-40S-like ribosome complex - state 2 |
rep, 1a-1b |
nsp1 |
pre-40S-like ribosome complex - state 2 |
~ |
32680882 |
3D view |
| 6ZMI |
ELECTRON MICROSCOPY |
2.6 |
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. |
SARS-CoV-2 Nsp1 bound to the human LYAR-80S ribosome complex |
rep, 1a-1b |
nsp1 |
human LYAR-80S ribosome complex |
~ |
32680882 |
3D view |
| 6ZMO |
ELECTRON MICROSCOPY |
3.1 |
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. |
SARS-CoV-2 Nsp1 bound to the human LYAR-80S-eEF1a ribosome complex |
rep, 1a-1b |
nsp1 |
LYAR-80S-eEF1a ribosome complex |
~ |
32680882 |
3D view |
| 6ZOJ |
ELECTRON MICROSCOPY |
2.8 |
SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. |
SARS-CoV-2-Nsp1-40S complex, composite map |
rep, 1a-1b |
nsp1 |
40S complex |
~ |
32908316 |
3D view |
| 6ZOK |
ELECTRON MICROSCOPY |
2.8 |
SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. |
SARS-CoV-2-Nsp1-40S complex, focused on body |
rep, 1a-1b |
nsp1 |
40S complex |
~ |
32908316 |
3D view |
| 6ZON |
ELECTRON MICROSCOPY |
3 |
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. |
SARS-CoV-2 Nsp1 bound to a human 43S preinitiation ribosome complex - state 1 |
rep, 1a-1b |
nsp1 |
human 43S preinitiation ribosome |
~ |
32680882 |
3D view |
| 6XMK |
X-RAY DIFFRACTION |
1.7 |
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. |
1.70 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 7j |
rep, 1a-1b |
3C-like proteinase |
7j |
~ |
32747425 |
3D view |
| 6Y2G |
X-RAY DIFFRACTION |
2.2 |
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. |
Crystal structure (orthorhombic form) of the complex resulting from the reaction between SARS-CoV-2 (2019-nCoV) main protease and tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b) |
rep, 1a-1b |
Replicase polyprotein 1ab |
tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b) |
~ |
32198291 |
3D view |
| 6XQB |
ELECTRON MICROSCOPY |
3.4 |
Structure of SARS-CoV-2 RdRp/RNA complex at 3.4 Angstroms resolution |
SARS-CoV-2 RdRp/RNA complex |
rep, 1a-1b |
RNA-directed RNA polymerase, nsp8, nsp7 |
RNA (5'-R(*GP*UP*GP*GP*GP*CP*CP*CP*A)-3') |
~ |
|
3D view |
| 6Y2F |
X-RAY DIFFRACTION |
1.95 |
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. |
Crystal structure (monoclinic form) of the complex resulting from the reaction between SARS-CoV-2 (2019-nCoV) main protease and tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b) |
rep, 1a-1b |
Replicase polyprotein 1ab |
tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b) |
~ |
32198291 |
3D view |
| 6XR3 |
X-RAY DIFFRACTION |
1.45 |
X-ray Structure of SARS-CoV-2 main protease bound to GRL-024-20 at 1.45 A |
X-ray Structure of SARS-CoV-2 main protease bound to GRL-024-20 at 1.45 A |
rep, 1a-1b |
3C-like proteinase |
GRL-024-20 |
~ |
|
3D view |
| 6XQT |
X-RAY DIFFRACTION |
2.3 |
Malleability of the SARS-CoV-2 3CL M pro Active-Site Cavity Facilitates Binding of Clinical Antivirals. |
Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Narlaprevir |
rep, 1a-1b |
3C-like proteinase |
Narlaprevir |
~ |
33152262 |
3D view |
| 6XQS |
X-RAY DIFFRACTION |
1.9 |
Malleability of the SARS-CoV-2 3CL M pro Active-Site Cavity Facilitates Binding of Clinical Antivirals. |
Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Telaprevir |
rep, 1a-1b |
3C-like proteinase |
Telaprevir |
~ |
33152262 |
3D view |
| 6XQU |
X-RAY DIFFRACTION |
2.2 |
Malleability of the SARS-CoV-2 3CL M pro Active-Site Cavity Facilitates Binding of Clinical Antivirals. |
Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Boceprevir |
rep, 1a-1b |
3C-like proteinase |
Boceprevir |
~ |
33152262 |
3D view |
| 6YHU |
X-RAY DIFFRACTION |
2 |
Structural analysis of the putative SARS-CoV-2 primase complex. |
Crystal structure of the nsp7-nsp8 complex of SARS-CoV-2 |
rep, 1a-1b |
Replicase polyprotein 1a (A, C chains) |
Replicase polyprotein 1a (B,D chains) |
rep,A01a-1b |
32535228 |
3D view |
| 6YLA |
X-RAY DIFFRACTION |
2.42 |
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. |
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab |
S,2 |
Spike glycoprotein (A,E chains) |
CR3022 Fab |
~ |
32585135 |
3D view |
| 6YM0 |
X-RAY DIFFRACTION |
4.36 |
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. |
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1) |
S,2 |
Spike glycoprotein |
CR3022 Fab |
~ |
32585135 |
3D view |
| 6YNQ |
X-RAY DIFFRACTION |
1.8 |
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
Structure of SARS-CoV-2 Main Protease bound to 2-Methyl-1-tetralone. |
rep, 1a-1b |
Replicase polyprotein 1ab |
2-Methyl-1-tetralone |
~ |
|
3D view |
| 6YOR |
ELECTRON MICROSCOPY |
3.3, 3.9 |
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. |
Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab |
S,2 |
Spike glycoprotein |
IgG H chain, IgG L chain |
~ |
32585135 |
3D view |
| 6Z2M |
X-RAY DIFFRACTION |
2.71 |
Structural characterisation of a nanobody derived from a naive library that neutralises SARS-CoV-2 |
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex |
S,2 |
Spike glycoprotein |
CR3022 antibody, H11-D4 |
~ |
|
3D view |
| 6Z2E |
X-RAY DIFFRACTION |
1.7 |
Crystal structure of SARS-CoV-2 Mpro in complex with the activity-based probe, biotin-PEG(4)-Abu-Tle-Leu-Gln-vinylsulfone |
Crystal structure of SARS-CoV-2 Mpro in complex with the activity-based probe, biotin-PEG(4)-Abu-Tle-Leu-Gln-vinylsulfone |
rep, 1a-1b |
Main Protease (Mpro) |
biotin-PEG(4)-Abu-Tle-Leu-Gln-vinylsulfone |
~ |
|
3D view |
| 6XHM |
X-RAY DIFFRACTION |
1.406 |
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. |
Covalent complex of SARS-CoV-2 main protease with N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide |
rep, 1a-1b |
3C-like proteinase |
N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide |
~ |
33054210 |
3D view |
| 6XIP |
X-RAY DIFFRACTION |
1.5 |
The 1.5 A Crystal Structure of the Co-factor Complex of NSP7 and the C-terminal Domain of NSP8 from SARS CoV-2 |
The 1.5 A Crystal Structure of the Co-factor Complex of NSP7 and the C-terminal Domain of NSP8 from SARS CoV-2 |
rep, 1a-1b |
nsp7 |
nsp8 |
rep, 1a-1b |
|
3D view |
| 6XKQ |
X-RAY DIFFRACTION |
2.55 |
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-250 |
S,2 |
Spike glycoprotein - S1 |
CV07-250 ( heavy and light chain) |
~ |
33058755 |
3D view |
| 6XKM |
X-RAY DIFFRACTION |
2.25 |
Room Temperature Structure of SARS-CoV-2 NSP10/NSP16 Methyltransferase in a Complex with SAM Determined by Fixed-Target Serial Crystallography |
Room Temperature Structure of SARS-CoV-2 NSP10/NSP16 Methyltransferase in a Complex with SAM Determined by Fixed-Target Serial Crystallography |
rep, 1a-1b |
2'-O-methyltransferase (nsp16), nsp10 |
SAM ( S-ADENOSYLMETHIONINE ) |
~ |
|
3D view |
| 6XKP |
X-RAY DIFFRACTION |
2.72 |
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270 |
S,2 |
Spike protein S1 |
CV07-270 (heavy and light chain) |
~ |
33058755 |
3D view |
| 6XM4 |
ELECTRON MICROSCOPY |
2.9 |
Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains |
Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 2 |
S,2 |
Spike glycoprotein |
|
|
32637958 |
3D view |
| 6XM3 |
ELECTRON MICROSCOPY |
2.9 |
Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains |
Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 1 |
S,2 |
Spike glycoprotein |
|
|
32637958 |
3D view |
| 6M17 |
ELECTRON MICROSCOPY |
2.9 |
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. |
The 2019-nCoV RBD/ACE2-B0AT1 complex |
S,2 |
Receptor binding domain |
1.Sodium-dependent neutral amino acid transporter B(0)AT1
2.Angiotensin-converting enzyme 2
|
SLC6A19, B0AT1, ACE2, UNQ868/PRO1885 |
32132184 |
3D view |
| 6M0J |
X-RAY DIFFRACTION |
2.45 |
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. |
Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with ACE2 |
S,2 |
Spikeglycoprotein RBD |
Angiotensin-converting enzyme 2 |
ACE2
UNQ868/PRO1885 |
32225176 |
3D view |
| 6M0K |
X-RAY DIFFRACTION |
1.504 |
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. |
The crystal structure of COVID-19 main protease in complex with an inhibitor 11b |
rep, 1a-1b |
Replicase polyprotein 1ab |
11b (inhibitor) |
~ |
32321856 |
3D view |
| 6M2N |
X-RAY DIFFRACTION |
2.198 |
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. |
SARS-CoV-2 3CL protease (3CL pro) in complex with a novel inhibitor |
rep, 1a-1b |
3CL protease |
Novel inhibitor |
~ |
32737471 |
3D view |
| 6LU7 |
X-RAY DIFFRACTION |
2.16 |
Structure of Mprofrom SARS-CoV-2 and discovery of its inhibitors. |
The crystal structure of COVID-19 main protease in complex with an inhibitor N3 |
rep, 1a-1b |
Main protease |
N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE |
~ |
32272481 |
3D view |
| 6M5I |
X-RAY DIFFRACTION |
2.496 |
Crystal structure of 2019-nCoV nsp7-nsp8c complex |
Crystal structure of 2019-nCoV nsp7-nsp8c complex |
rep, 1a-1b |
NSP 8 |
NSP 7 |
rep, 1a-1b |
to be published |
3D view |
| 6M71 |
ELECTRON MICROSCOPY |
2.9 |
Structure of the RNA-dependent RNA polymerase from COVID-19 virus. |
SARS-Cov-2 RNA-dependent RNA polymerase in complex with cofactors |
rep, 1a-1b |
NSP 12 ( A chain ) |
NSP 7 (C chain)
NSP 8 (B, D chains) |
rep,A01a-1b |
32277040 |
3D view |
| 6LZE |
X-RAY DIFFRACTION |
1.505 |
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. |
The crystal structure of COVID-19 main protease in complex with an inhibitor 11a |
rep, 1a-1b |
Replicase polyprotein 1ab |
11a |
|
32321856 |
3D view |
| 6LZG |
X-RAY DIFFRACTION |
2.5 |
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. |
Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2 |
S,2 |
Spike glycoprotein |
Angiotensin-converting enzyme 2 |
ACE2, UNQ868/PRO1885 |
32275855 |
3D view |
| 5R84 |
X-RAY DIFFRACTION |
1.83 |
PanDDA analysis of COVID-19 main protease against the DSI-poised Fragment Library |
PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z31792168 |
rep, 1a-1b |
3C-like proteinase |
Z31792168 |
~ |
To be published |
3D view |
| 5R83 |
X-RAY DIFFRACTION |
1.58 |
PanDDA analysis of COVID-19 main protease against the DSI-poised Fragment Library |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z44592329 |
rep, 1a-1b |
3C-like proteinase |
Z44592329 |
~ |
To be published |
3D view |
| 5R7Y |
X-RAY DIFFRACTION |
1.65 |
PanDDA analysis of COVID-19 main protease against the DSI-poised Fragment Library |
PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z45617795 |
rep, 1a-1b |
3C-like proteinase |
Z45617795 |
~ |
To be published |
3D view |
| 5R80 |
X-RAY DIFFRACTION |
1.93 |
PanDDA analysis of COVID-19 main protease against the DSI-poised Fragment Library |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z18197050 |
rep, 1a-1b |
3C-like proteinase |
Z18197050 |
~ |
To be published |
3D view |
| 5R82 |
X-RAY DIFFRACTION |
1.31 |
PanDDA analysis of COVID-19 main protease against the DSI-poised Fragment Library |
PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z219104216 |
rep, 1a-1b |
3C-like proteinase |
Z219104216 |
~ |
To be published |
3D view |
| 5R81 |
X-RAY DIFFRACTION |
1.95 |
PanDDA analysis of COVID-19 main protease against the DSI-poised Fragment Library |
PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z1367324110 |
rep, 1a-1b |
3C-like proteinase |
Z1367324110 |
~ |
To be published |
3D view |
| 5R8T |
X-RAY DIFFRACTION |
1.27 |
PanDDA analysis group deposition of ground-state model of SARS-CoV-2 main protease fragment screening |
PanDDA analysis group deposition of ground-state model of SARS-CoV-2 main protease screened against DSI poised (Enamine), Fraglites and Peplites (Newcastle university), Mini Frags (Astex), York 3D (York university), electrophile cysteine covalent (Weizman institute) fragment libraries |
rep, 1a-1b |
3C-like proteinase |
|
|
|
3D view |
| 5R7Z |
X-RAY DIFFRACTION |
1.59 |
PanDDA analysis of COVID-19 main protease against the DSI-poised Fragment Library |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1220452176 |
rep, 1a-1b |
3C-like proteinase |
Z1220452176 |
~ |
To be published |
3D view |
| 5REA |
X-RAY DIFFRACTION |
1.63 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z31432226 |
rep, 1a-1b |
3C-like proteinase |
Z31432226 |
~ |
To be published |
3D view |
| 5REC |
X-RAY DIFFRACTION |
1.73 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1587220559 |
rep, 1a-1b |
3C-like proteinase |
Z1587220559 |
~ |
To be published |
3D view |
| 5REB |
X-RAY DIFFRACTION |
1.68 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434899 |
rep, 1a-1b |
3C-like proteinase |
Z2856434899 |
~ |
To be published |
3D view |
| 5REE |
X-RAY DIFFRACTION |
1.77 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2217052426 |
rep, 1a-1b |
3C-like proteinase |
Z2217052426 |
~ |
to be published |
3D view |
| 5RED |
X-RAY DIFFRACTION |
1.47 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434865 |
rep, 1a-1b |
3C-like proteinase |
Z2856434865 |
~ |
to be published |
3D view |
| 5REG |
X-RAY DIFFRACTION |
1.67 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1545313172 |
rep, 1a-1b |
3C-like proteinase |
Z1545313172 |
~ |
To be published |
3D view |
| 5REF |
X-RAY DIFFRACTION |
1.61 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z24758179 |
rep, 1a-1b |
3C-like proteinase |
Z24758179 |
~ |
To be published |
3D view |
| 5RE9 |
X-RAY DIFFRACTION |
1.72 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434836 |
rep, 1a-1b |
3C-like proteinase |
Z2856434836 |
~ |
To be published |
3D view |
| 5RE8 |
X-RAY DIFFRACTION |
1.81 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2737076969 |
rep, 1a-1b |
3C-like proteinase |
Z2737076969 |
~ |
To be published |
3D view |
| 5RE5 |
X-RAY DIFFRACTION |
2.07 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z33545544 |
rep, 1a-1b |
3C-like proteinase |
Z33545544 |
~ |
To be published |
3D view |
| 5RE4 |
X-RAY DIFFRACTION |
1.88 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1129283193 |
rep, 1a-1b |
3C-like proteinase |
Z1129283193 |
~ |
To be published |
3D view |
| 5RE7 |
X-RAY DIFFRACTION |
1.79 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z30932204 |
rep, 1a-1b |
3C-like proteinase |
Z30932204 |
~ |
To be published |
3D view |
| 5RE6 |
X-RAY DIFFRACTION |
1.87 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z54571979 |
rep, 1a-1b |
3C-like proteinase |
Z54571979 |
~ |
To be published |
3D view |
| 5RFB |
X-RAY DIFFRACTION |
1.48 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1271660837 |
rep, 1a-1b |
3C-like proteinase |
Z1271660837 |
~ |
To be published |
3D view |
| 5RFA |
X-RAY DIFFRACTION |
1.52 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2643472210 |
rep, 1a-1b |
3C-like proteinase |
Z2643472210 |
~ |
To be published |
3D view |
| 5RFD |
X-RAY DIFFRACTION |
1.41 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z126932614 |
rep, 1a-1b |
3C-like proteinase |
Z126932614 |
~ |
To be published |
3D view |
| 5RFC |
X-RAY DIFFRACTION |
1.4 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z979145504 |
rep, 1a-1b |
3C-like proteinase |
Z979145504 |
~ |
To be published |
3D view |
| 5RFF |
X-RAY DIFFRACTION |
1.78 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102704 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102704 |
~ |
To be published |
3D view |
| 5RFE |
X-RAY DIFFRACTION |
1.46 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z509756472 |
rep, 1a-1b |
3C-like proteinase |
Z509756472 |
~ |
To be published |
3D view |
| 5RFH |
X-RAY DIFFRACTION |
1.58 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102277 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102277 |
~ |
To be published |
3D view |
| 5RFG |
X-RAY DIFFRACTION |
2.32 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102372 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102372 |
~ |
To be published |
3D view |
| 5REY |
X-RAY DIFFRACTION |
1.96 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102911 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102911 |
~ |
To be published |
3D view |
| 5REX |
X-RAY DIFFRACTION |
2.07 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102287 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102287 |
~ |
To be published |
3D view |
| 5RF9 |
X-RAY DIFFRACTION |
1.43 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z217038356 |
rep, 1a-1b |
3C-like proteinase |
Z217038356 |
~ |
To be published |
3D view |
| 5REZ |
X-RAY DIFFRACTION |
1.79 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with POB0129 |
rep, 1a-1b |
3C-like proteinase |
POB0129 |
~ |
To be published |
3D view |
| 5RF2 |
X-RAY DIFFRACTION |
1.53 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1741969146 |
rep, 1a-1b |
3C-like proteinase |
Z1741969146 |
~ |
To be published |
3D view |
| 5REP |
X-RAY DIFFRACTION |
1.81 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102201 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102201 |
~ |
To be published |
3D view |
| 5RF1 |
X-RAY DIFFRACTION |
1.73 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with NCL-00023830 |
rep, 1a-1b |
3C-like proteinase |
NCL-00023830 |
~ |
To be published |
3D view |
| 5RES |
X-RAY DIFFRACTION |
1.65 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102281 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102281 |
~ |
To be published |
3D view |
| 5RF4 |
X-RAY DIFFRACTION |
1.61 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1741982125 |
rep, 1a-1b |
3C-like proteinase |
Z1741982125 |
~ |
To be published |
3D view |
| 5RER |
X-RAY DIFFRACTION |
1.88 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102615 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102615 |
~ |
To be published |
3D view |
| 5RF3 |
X-RAY DIFFRACTION |
1.5 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1741970824 |
rep, 1a-1b |
3C-like proteinase |
Z1741970824 |
~ |
To be published |
3D view |
| 5REU |
X-RAY DIFFRACTION |
1.69 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102395 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102395 |
~ |
To be published |
3D view |
| 5RF6 |
X-RAY DIFFRACTION |
1.45 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1348371854 |
rep, 1a-1b |
3C-like proteinase |
Z1348371854 |
~ |
To be published |
3D view |
| 5RET |
X-RAY DIFFRACTION |
1.68 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102269 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102269 |
~ |
To be published |
3D view |
| 5RF5 |
X-RAY DIFFRACTION |
1.74 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z3241250482 |
rep, 1a-1b |
3C-like proteinase |
Z3241250482 |
~ |
To be published |
3D view |
| 5REW |
X-RAY DIFFRACTION |
1.55 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102275 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102275 |
~ |
To be published |
3D view |
| 5RF8 |
X-RAY DIFFRACTION |
1.44 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z271004858 |
rep, 1a-1b |
3C-like proteinase |
Z271004858 |
~ |
To be published |
3D view |
| 5REV |
X-RAY DIFFRACTION |
1.6 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0103072 |
rep, 1a-1b |
3C-like proteinase |
PCM-0103072 |
~ |
To be published |
3D view |
| 5RF7 |
X-RAY DIFFRACTION |
1.54 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z316425948_minor |
rep, 1a-1b |
3C-like proteinase |
Z316425948_minor |
~ |
To be published |
3D view |
| 5REI |
X-RAY DIFFRACTION |
1.82 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434856 |
rep, 1a-1b |
3C-like proteinase |
Z2856434856 |
~ |
To be published |
3D view |
| 5REH |
X-RAY DIFFRACTION |
1.8 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z111507846 |
rep, 1a-1b |
3C-like proteinase |
Z111507846 |
~ |
To be published |
3D view |
| 5REK |
X-RAY DIFFRACTION |
1.74 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102327 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102327 |
~ |
To be published |
3D view |
| 5REJ |
X-RAY DIFFRACTION |
1.72 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102241 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102241 |
~ |
To be published |
3D view |
| 5REM |
X-RAY DIFFRACTION |
1.96 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0103016 |
rep, 1a-1b |
3C-like proteinase |
PCM-0103016 |
~ |
To be published |
3D view |
| 5REL |
X-RAY DIFFRACTION |
1.62 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102340 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102340 |
~ |
To be published |
3D view |
| 5REO |
X-RAY DIFFRACTION |
1.88 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102578 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102578 |
~ |
To be published |
3D view |
| 5RF0 |
X-RAY DIFFRACTION |
1.65 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with POB0073 |
rep, 1a-1b |
3C-like proteinase |
POB0073 |
~ |
To be published |
3D view |
| 5REN |
X-RAY DIFFRACTION |
2.15 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102425 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102425 |
~ |
To be published |
3D view |
| 5RGG |
X-RAY DIFFRACTION |
2.26 |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434890 (Mpro-x0165) |
rep, 1a-1b |
3C-like proteinase |
Z2856434890 |
~ |
To be published |
3D view |
| 5RGI |
X-RAY DIFFRACTION |
1.57 |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z369936976 (Mpro-x0397) |
rep, 1a-1b |
3C-like proteinase |
Z369936976 |
~ |
To be published |
3D view |
| 5RGH |
X-RAY DIFFRACTION |
1.7 |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1619978933 (Mpro-x0395) |
rep, 1a-1b |
3C-like proteinase |
Z1619978933 |
~ |
To be published |
3D view |
| 5RFZ |
X-RAY DIFFRACTION |
1.68 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102274 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102274 |
~ |
To be published |
3D view |
| 5RFY |
X-RAY DIFFRACTION |
1.9 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102974 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102974 |
~ |
to be published |
3D view |
| 5RFR |
X-RAY DIFFRACTION |
1.71 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102169 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102169 |
~ |
to be published |
3D view |
| 5RG3 |
X-RAY DIFFRACTION |
1.58 |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with NCL-00025412 |
rep, 1a-1b |
3C-like proteinase |
NCL-00025412 |
~ |
To be published |
3D view |
| 5RFQ |
X-RAY DIFFRACTION |
1.76 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102179 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102179 |
~ |
To be published |
3D view |
| 5RG2 |
X-RAY DIFFRACTION |
1.63 |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen |
PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with NCL-00025058 |
rep, 1a-1b |
3C-like proteinase |
NCL-00025058 |
~ |
To be published |
3D view |
| 5RFT |
X-RAY DIFFRACTION |
1.58 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102432 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102432 |
~ |
To be published |
3D view |
| 5RFS |
X-RAY DIFFRACTION |
1.7 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102739 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102739 |
~ |
To be published |
3D view |
| 5RFV |
X-RAY DIFFRACTION |
1.48 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102306 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102306 |
~ |
To be published |
3D view |
| 5RFU |
X-RAY DIFFRACTION |
1.53 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102121 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102121 |
~ |
To be published |
3D view |
| 5RFX |
X-RAY DIFFRACTION |
1.55 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102254 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102254 |
~ |
To be published |
3D view |
| 5RFW |
X-RAY DIFFRACTION |
1.43 |
PanDDA analysis group deposition of SARS-CoV-2 mainprotease fragment screen |
PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102243 |
rep, 1a-1b |
3C-like proteinase |
PCM-0102243 |
~ |
To be published |
3D view |